Safety and efficacy of eblasakimab, an IL-13Rα1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: a phase 1b, multiple-ascending dose study

By sjmartinez • October 23, 2023

Veverka KA, Thng STG, Silverberg JI, Armstrong AW, Menezes J, Kaoukhov A, Blauvelt A. Safety and efficacy of eblasakimab, an IL-13Rα1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: a phase 1b, multiple-ascending dose study. J Am Acad Dermatol. 2023 Oct 20:S0190-9622(23)03029-3. doi: 10.1016/j.jaad.2023.10.026. Epub ahead of print. PMID: 37866456.

Tags: atopic dermatitis, Dermatology, EASI, eblasakimab, IL-13, IL-4, moderate-to-severe AD, pruritus, Publications, type 2 inflammation

Increased mitochondrial mutation heteroplasmy induces aging phenotypes in pluripotent stem cells and their differentiated progeny

Vandiver AR, Torres A Jr, Sanden A, Nguyen TL, Gasilla J, Doan MT, Martirosian V, Hoang A, Wanagat J, Teitell MA. Increased mitochondrial mutation heteroplasmy[...]

Update on Absorbable Facial Thread Lifts

Riopelle AM, Geisler AN, Eber A, Dover JS. Update on Absorbable Facial Thread Lifts. Dermatol Surg. 2024 Dec 11. doi: 10.1097/DSS.0000000000004521. Epub ahead of print.[...]

Unusual Cutaneous Metastasis in a Patient with Cholangiocarcinoma

Dong E, Yashar S, Mandelkern M, Kaunitz J. Unusual Cutaneous Metastasis in a Patient with Cholangiocarcinoma. Dig Dis Sci. 2024 Dec 11. doi: 10.1007/s10620-024-08775-1. Epub[...]